NEW YORK, March 25, 2024 /PRNewswire/ -- In the era medical breakthroughs, advancements in Diffuse Large B-Cell Lymphoma (DLBCL) therapeutics stand out as a beacon of hope. The diffuse large B-cell lymphoma (DLBCL) therapeutics market size is forecasted to witness remarkable growth from 2023 to 2027, with an estimated increase of USD 2,061.88 million and a CAGR of 7.96%.For more insights on the historic data (2017 to 2021) and forecast market size (2023 to 2027) – Request a report sample.

纽约，2024年3月25日/PRNewswire/--在医学突破的时代，弥漫性大B细胞淋巴瘤（DLBCL）治疗的进步成为希望的灯塔。预计从2023年到2027年，弥漫性大B细胞淋巴瘤（DLBCL）治疗剂的市场规模将显着增长，估计增加206188万美元，复合年增长率为7.96%。有关历史数据（2017年至2021年）和预测市场规模（2023年至2027年）的更多见解，请索取报告样本。

Continue Reading

继续阅读

Technavio has announced its latest market research report titled Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2023-2027

Technavio宣布了其最新的市场研究报告，题为《2023-2027年全球弥漫性大B细胞淋巴瘤（DLBCL）治疗市场》

What fuels this growth?

是什么推动了这种增长？

Several factors come into play. The rise in the geriatric population, coupled with an increasing incidence of DLBCL, propels the demand for innovative treatments. Notably, the approval of therapeutics for patients with relapsed or refractory DLBCL marks a significant stride in this journey.One of the key drivers of this growth is the continuous focus on regulatory approvals for therapeutics tailored to the needs of patients with relapsed or refractory DLBCL.

有几个因素起作用。老年人口的增加，加上DLBCL发病率的增加，推动了对创新治疗的需求。值得注意的是，对复发或难治性DLBCL患者的治疗方法的批准标志着这一旅程的重大进步。这种增长的关键驱动因素之一是持续关注针对复发或难治性DLBCL患者需求的治疗药物的监管批准。

For instance, Bristol Myers Squibb received approval for lisocabtagene maraleucel (liso-cel, Breyanzi), a CAR T-cell therapy indicated for various types of lymphoma, including DLBCL. Similarly, ADC Therapeutics SA's Biologics License Application for loncastuximab tesirine (Lonca) was accepted by the US FDA, offering another ray of hope for patients battling DLBCL.For more insights on the historic data (2017 to 2021) and forecast market size (2023 to 2027) – Request a report sampleMoreover, technological advances are revolutionizing the landscape of DLBCL treatment.

例如，百时美施贵宝（Bristol-Myers Squibb）获得了lisocbatagene maraluecel（liso-cel，Breyanzi）的批准，这是一种CAR T细胞疗法，适用于各种类型的淋巴瘤，包括DLBCL。同样，美国FDA接受了ADC Therapeutics SA的loncastuximab tesirine（Lonca）生物制剂许可证申请，为与DLBCL斗争的患者带来了另一缕希望。有关历史数据（2017年至2021年）和预测市场规模（2023年至2027年）的更多见解，请索取报告样本。此外，技术进步正在彻底改变DLBCL治疗的格局。

From chimeric antigen receptor (CAR) T-cell therapy to gene therapy, companies like Novartis and Gilead are pioneering innovative therapies that promise increased efficacy and reduced treatment efforts.However, amidst this progress, challenges persist. The high cost of DLBCL treatment remains a major hurdle, hindering market growth.

从嵌合抗原受体（CAR）T细胞疗法到基因疗法，诺华（Novartis）和吉利德（Gilead）等公司正在开创创新疗法，有望提高疗效并减少治疗工作量。然而，在这一进展中，挑战依然存在。DLBCL治疗的高成本仍然是一个主要障碍，阻碍了市场的增长。

Drugs like vincristine, doxorubicin, and prednisone come with hefty price tags, and chemotherapy prolongs treatment duration, further escalating costs. Additionally, inadequate distribution networks in underdeveloped regions exacerbate the issue, posing challenges in access to essential therapeutics.For more insights on the historic data (2017 to 2021) and forecast market size (2023 to 2027) – Request a report sampleDespite ch.

长春新碱、多柔比星和泼尼松等药物价格高昂，化疗延长了治疗时间，进一步增加了成本。此外，不发达地区的分销网络不足加剧了这一问题，对获得基本疗法提出了挑战。有关历史数据（2017年至2021年）和预测市场规模（2023年至2027年）的更多见解，请尽管ch。

The bispecific antibodies for cancer market is estimated to grow at a CAGR of 8.82% between 2022 and 2027. The size of the market is forecast to increase by USD 400.72 million. The increasing prevalence of cancer is notably driving the market growth, although factors such as the high cost of drugs may impede the market growth..

据估计，2022年至2027年间，癌症市场的双特异性抗体的复合年增长率为8.82%。预计市场规模将增加40072万美元。尽管药物成本高等因素可能会阻碍市场的增长，但癌症患病率的增加显着推动了市场的增长。。

The gene therapy market is estimated to grow at a CAGR of 19.91% between 2022 and 2027. The size of the market is forecast to increase by USD 4,613.9 million. The increase in special drug designations is notably driving the cell and gene therapy market growth, although factors such as the high treatment cost may impede the market growth..

据估计，2022年至2027年间，基因治疗市场的复合年增长率为19.91%。预计市场规模将增加461390万美元。特殊药物名称的增加显着推动了细胞和基因治疗市场的增长，尽管高治疗成本等因素可能会阻碍市场的增长。。

Table of contents:1 Executive Summary2 Landscape3 Sizing4 Historic Size5 Five Forces Analysis6 Segmentations7 Customer Landscape8 Geographic Landscape9 Drivers, Challenges, and Trends10 Vendor Landscape11 Vendor Analysis12 AppendixAbout USTechnavio is a leading global technology research and advisory company.

目录：1执行摘要2景观3规模4历史规模5五力分析6细分7客户景观8地理景观9驱动因素、挑战和趋势10供应商景观11供应商分析12附录关于USTechnavio是一家领先的全球技术研究和咨询公司。

Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries.

他们的研究和分析侧重于新兴市场趋势，并提供可行的见解，以帮助企业识别市场机会并制定有效的战略来优化其市场地位。Technavio的报告库拥有500多名专业分析师，由17000多份报告和统计数据组成，涵盖了50个国家的800多种技术。

Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.ContactTechnavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.comWebsite: www.technavio.com/SOURCE Technavio.

他们的客户群包括各种规模的企业，包括100多家财富500强公司。这一不断增长的客户群依靠Technavio的全面覆盖范围、广泛的研究和可行的市场见解来确定现有和潜在市场的机会，并评估其在不断变化的市场情景中的竞争地位。联系TechNavio Research Jesse MaidaMedia&Marketing ExecutiveUS：+1 844 364 1100UK：+44 203 893 3200电子邮件：media@technavio.comWebsite：www.technavio.com/SOURCE technavio。